FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966676810> ?p ?o ?g. }

• W1966676810 endingPage "1316" @default.
• W1966676810 startingPage "1310" @default.
• W1966676810 abstract "Thirty B-cell chronic lymphocytic leukemia patients were treated with fludarabine-cyclophosphamide-rituximab (FCR) and immune cell counts (natural killer (NK) cells, CD4, CD8, Tgammadelta and monocytes) were monitored from the end of treatment (EOT) up to 36 months (M36). Moreover, nonleukemic peripheral blood lymphocyte cytotoxicity (PBL/CTC) as well as rituximab (RTX)-dependent PBL/CTC was also measured at the initiation of therapy, EOT and M12. These parameters were correlated with post-FCR monitoring of the minimal residual disease (MRD) level in blood using a four-color flow cytometry technique. FCR induced a profound and sustained depletion of all T-cell populations, Tgammadelta being the most affected, whereas NK cells were relatively preserved. Both basal and interleukin-2-stimulated nonleukemic PBL/CTC against MEC-2, a CLL cell line, increased during the post-FCR period. There was no correlation between immune recovery parameters and MRD progression profile, except that patients with high post-FCR CD4(+) counts experienced rapid MRD progression. MRD at M12 predicts clinical relapse. The limited data show RTX-mediated LBL/CTC activity against autologous B-cell cells in individuals with <1% residual disease at M12, opening avenues for immunomodulation post-FCR with anti-CD20 antibodies. To conclude, our study suggests that MRD increase at M12 precedes disease evolution post-FCR, and should be assessed as a surrogate marker for proactive management of CLL relapse." @default.
• W1966676810 created "2016-06-24" @default.
• W1966676810 creator A5011186902 @default.
• W1966676810 creator A5013649293 @default.
• W1966676810 creator A5020087486 @default.
• W1966676810 creator A5030565933 @default.
• W1966676810 creator A5045290554 @default.
• W1966676810 creator A5060529868 @default.
• W1966676810 creator A5066579812 @default.
• W1966676810 creator A5070615970 @default.
• W1966676810 date "2010-05-13" @default.
• W1966676810 modified "2023-10-15" @default.
• W1966676810 title "Immune recovery after fludarabine–cyclophosphamide–rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy" @default.
• W1966676810 cites W1553227584 @default.
• W1966676810 cites W1906996655 @default.
• W1966676810 cites W1985565700 @default.
• W1966676810 cites W1985600634 @default.
• W1966676810 cites W1994820184 @default.
• W1966676810 cites W2001850157 @default.
• W1966676810 cites W2012630504 @default.
• W1966676810 cites W2014651277 @default.
• W1966676810 cites W2040585498 @default.
• W1966676810 cites W2065176660 @default.
• W1966676810 cites W2072395096 @default.
• W1966676810 cites W2083318946 @default.
• W1966676810 cites W2097191776 @default.
• W1966676810 cites W2098166849 @default.
• W1966676810 cites W2099308699 @default.
• W1966676810 cites W2129945230 @default.
• W1966676810 cites W2142099365 @default.
• W1966676810 cites W2156824251 @default.
• W1966676810 cites W2164982544 @default.
• W1966676810 cites W2348637346 @default.
• W1966676810 cites W2587128734 @default.
• W1966676810 cites W2993990382 @default.
• W1966676810 cites W96780237 @default.
• W1966676810 doi "https://doi.org/10.1038/leu.2010.89" @default.
• W1966676810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20463751" @default.
• W1966676810 hasPublicationYear "2010" @default.
• W1966676810 type Work @default.
• W1966676810 sameAs 1966676810 @default.
• W1966676810 citedByCount "46" @default.
• W1966676810 countsByYear W19666768102012 @default.
• W1966676810 countsByYear W19666768102013 @default.
• W1966676810 countsByYear W19666768102014 @default.
• W1966676810 countsByYear W19666768102015 @default.
• W1966676810 countsByYear W19666768102016 @default.
• W1966676810 countsByYear W19666768102017 @default.
• W1966676810 countsByYear W19666768102018 @default.
• W1966676810 countsByYear W19666768102019 @default.
• W1966676810 countsByYear W19666768102020 @default.
• W1966676810 countsByYear W19666768102021 @default.
• W1966676810 countsByYear W19666768102022 @default.
• W1966676810 crossrefType "journal-article" @default.
• W1966676810 hasAuthorship W1966676810A5011186902 @default.
• W1966676810 hasAuthorship W1966676810A5013649293 @default.
• W1966676810 hasAuthorship W1966676810A5020087486 @default.
• W1966676810 hasAuthorship W1966676810A5030565933 @default.
• W1966676810 hasAuthorship W1966676810A5045290554 @default.
• W1966676810 hasAuthorship W1966676810A5060529868 @default.
• W1966676810 hasAuthorship W1966676810A5066579812 @default.
• W1966676810 hasAuthorship W1966676810A5070615970 @default.
• W1966676810 hasBestOaLocation W19666768101 @default.
• W1966676810 hasConcept C126322002 @default.
• W1966676810 hasConcept C159654299 @default.
• W1966676810 hasConcept C167672396 @default.
• W1966676810 hasConcept C18031839 @default.
• W1966676810 hasConcept C196166836 @default.
• W1966676810 hasConcept C203014093 @default.
• W1966676810 hasConcept C2776694085 @default.
• W1966676810 hasConcept C2776755627 @default.
• W1966676810 hasConcept C2777701055 @default.
• W1966676810 hasConcept C2777761686 @default.
• W1966676810 hasConcept C2777938653 @default.
• W1966676810 hasConcept C2778461978 @default.
• W1966676810 hasConcept C2779263901 @default.
• W1966676810 hasConcept C2779823535 @default.
• W1966676810 hasConcept C2780653079 @default.
• W1966676810 hasConcept C553184892 @default.
• W1966676810 hasConcept C71924100 @default.
• W1966676810 hasConcept C8891405 @default.
• W1966676810 hasConceptScore W1966676810C126322002 @default.
• W1966676810 hasConceptScore W1966676810C159654299 @default.
• W1966676810 hasConceptScore W1966676810C167672396 @default.
• W1966676810 hasConceptScore W1966676810C18031839 @default.
• W1966676810 hasConceptScore W1966676810C196166836 @default.
• W1966676810 hasConceptScore W1966676810C203014093 @default.
• W1966676810 hasConceptScore W1966676810C2776694085 @default.
• W1966676810 hasConceptScore W1966676810C2776755627 @default.
• W1966676810 hasConceptScore W1966676810C2777701055 @default.
• W1966676810 hasConceptScore W1966676810C2777761686 @default.
• W1966676810 hasConceptScore W1966676810C2777938653 @default.
• W1966676810 hasConceptScore W1966676810C2778461978 @default.
• W1966676810 hasConceptScore W1966676810C2779263901 @default.
• W1966676810 hasConceptScore W1966676810C2779823535 @default.
• W1966676810 hasConceptScore W1966676810C2780653079 @default.
• W1966676810 hasConceptScore W1966676810C553184892 @default.
• W1966676810 hasConceptScore W1966676810C71924100 @default.

• next